Compare Aegon Ltd. (AEG) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs BridgeBio Pharma Inc — how do they compare? Aegon Ltd. trades at $9.4 (market cap $14.16B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Aegon Ltd. pays a 4.9% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AEG | BBIO | |
|---|---|---|
Market Cap | $14.16B | $16.61B |
Sector | Financials | Health |
52-Week High | $9.53 | $90.17 |
52-Week Low | $6.79 | $47.29 |
Enterprise Value | $15.31B | $18.16B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.53, up 0.74% on the day, with a bullish technical signal driven by moving averages. The company reported revenue of $19.52 billion in 2024 with a net income margin of 3.64%, and recent earnings show mixed results with beats in Q2 and Q3 2025 but a miss in Q4. A dividend of $0.25 is scheduled for July 2026. The balance sheet shows total assets of $327.39 billion and a debt-to-asset ratio improving to 1.46 in 2024.
The outlook is cautiously optimistic with a P/E of 13.74 and P/S of 0.58 suggesting reasonable valuation, but risks include volatile cash flows and competitive pressures. Analyst sentiment is mixed with 27.78% buy ratings, highlighting potential for growth amid execution challenges.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
